Delving into the Latest Updates on N-6022 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

GSNOR

Action

inhibitors

Mechanism

GSNOR inhibitors(alcohol dehydrogenase 5 (class III), chi polypeptide inhibitors)

Therapeutic Areas

NeoplasmsNervous System Diseases

Active Indication

Brain Cancer

Inactive Indication

AsthmaCystic FibrosisInflammatory Bowel Diseases+ [1]

Originator Organization

Nivalis Therapeutics, Inc.

Active Organization

Texas Tech University Health Sciences Center

Inactive Organization

Nivalis Therapeutics, Inc.

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC24H22N4O3

InChIKeyYVPGZQLRPAGKLA-UHFFFAOYSA-N

CAS Registry1208315-24-5

This Phase 1 study will evaluate multiple doses across a range that has been found to be effective in mouse models of asthma and safe in one Phase 1 clinical trial. It is intended to provide evidence of the tolerability of multiple doses as well as provide information on the Pharmacokinetic (PK) and metabolism of N6022 in humans.

Start Date01 Apr 2011

Sponsor / Collaborator

Nivalis Therapeutics, Inc.

NCT01316315

/ CompletedPhase 1/2

A Double-Blind, Randomized, Placebo-Controlled, Two-Period, Cross-Over Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma

The purpose of this study is to determine whether a single IV dose of N6022 will have a significant bronchoprotective effect, compared with placebo, during methacholine challenge.

Start Date01 Mar 2011

Sponsor / Collaborator

Nivalis Therapeutics, Inc.

100 Clinical Results associated with N-6022

Login to view more data

100 Translational Medicine associated with N-6022

Login to view more data

100 Patents (Medical) associated with N-6022

Login to view more data

33

Literatures (Medical) associated with N-6022

01 Jan 2025·Neuroscience

The role of S-nitrosoglutathione reductase (GSNOR) in T cell-mediated immunopathology of experimental autoimmune encephalomyelitis (EAE)

Article

Author: Kim, Judong ; Touhidul Islam, S.M. ; Singh, Avtar K ; Singh, Inderjit ; Fei, Qiao ; Touhidul Islam, S M ; Won, Jeseong

Previously, we reported that both S-nitrosoglutathione (GSNO), a carrier of cellular nitric oxide, and N6022, an injectable form of GSNO reductase (GSNOR) inhibitor that increases endogenous GSNO levels, alleviate experimental autoimmune encephalomyelitis (EAE) in mice by suppressing Th1 and Th17 immune responses. Building on these findings, we explored the role of GSNOR in EAE pathogenesis and evaluated the efficacy of an orally active GSNOR inhibitor (N91115) in treating the EAE disease. EAE mice exhibited heightened expression/activity of GSNOR in the spinal cord, and the knockout of the GSNOR gene resulted in much milder clinical manifestations of EAE, with lower degrees of demyelination and axonal loss, reduced microglial and astrocyte activations, as well as suppressed Th1 and Th17 cell responses, alongside bolstered Treg immune responses. Next, we evaluated the efficacy of N91115 against EAE immunopathology. Consistent with our findings in GSNOR deficient EAE mice, daily N91115 administration reduced clinical EAE severity, with less spinal cord demyelination and axonal loss compared to untreated EAE mice. Furthermore, N91115 treated EAE mice showed diminished Th1 and Th17 immune responses and enhanced Treg responses. This observation underscores the potential of increased GSNOR expression and activity as a risk factor exacerbating EAE immunopathology, while simultaneously highlighting its potential as a target for modifying the disease. Furthermore, the balanced immune regulation provided by orally active N91115 (IL-6/IL-17a vs. IL-10) presents a promising alternative to immunosuppressive drugs, reducing the risk of opportunistic infections.

01 Oct 2024·Plant Physiology and Biochemistry

NRT2.1 mediates the reciprocal regulation of nitrate and NO/SNO in seedling leaves of Fraxinus mandshurica and Betula platyphylla

Article

Author: Yang, Haixin ; Wang, Bo ; Li, Xiaoshuang ; Han, Shuyi ; Fan, Guizhi ; Zhan, Yaguang

Nitric oxide (NO) and S-nitrosothiol (SNO) are signal molecules and the products of nitrogen metabolism. Nitrate (NO₃^-) is the main nitrogen source, and nitrate transporters (NRTs) are responsible for NO₃^- absorption or transport. However, the interactive effect between NO₃^-/NRT and NO/SNO in tree plants remains ambiguous. In the present study, 25 mmol L^-1 NO₃^- and 1 mmol L^-1 NO donor sodium nitroprusside (SNP) treatment that was conducted for 24 h enhanced NO/SNO and NO₃^- metabolism, whereas 2.5 mmol L^-1 NO₃^- and 80 μmol L^-1 N6022 (a compound that increases SNO content) treatment reduced them in seedling leaves of Fraxinus mandshurica and Betula platyphylla. Among the nine NRT family members examined, the gene expression level of NRT2.1 had a greater response to NO/SNO and NO₃^- treatment in the seedling leaves of F. mandshurica and B. platyphylla. Meanwhile, FmNRT2.1 mediated NO and SNO production in seedling leaves of F. mandshurica using Agrobacterium-mediated transient transformation. These findings shed light on the reciprocal regulation between NO₃^- and NO/SNO in seedlings of F. mandshurica and B. platyphylla, and NRT2.1 may act as a key regulatory hub.

01 Jun 2024·European Journal of Pharmacology

N6022 attenuates cerebral ischemia/reperfusion injury-induced microglia ferroptosis by promoting Nrf2 nuclear translocation and inhibiting the GSNOR/GSTP1 axis

Article

Author: Han, Bo ; Ma, Ya-Ping ; He, Mao-Tao ; Li, P Andy ; Dong, Hao ; Duan, Wan-Li ; Zhang, Bao-Gang ; Ma, Chang-Sheng ; Wang, Xue-Jie ; Sheng, Zhi-Mei ; Zhang, Li-Ying

Stroke poses a significant risk of mortality, particularly among the elderly population. The pathophysiological process of ischemic stroke is complex, and it is crucial to elucidate its molecular mechanisms and explore potential protective drugs. Ferroptosis, a newly recognized form of programmed cell death distinct from necrosis, apoptosis, and autophagy, is closely associated with the pathophysiology of ischemic stroke. N6022, a selective inhibitor of S-nitrosoglutathione reductase (GSNOR), is a "first-in-class" drug for asthma with potential therapeutic applications. However, it remains unclear whether N6022 exerts protective effects in ischemic stroke, and the precise mechanisms of its action are unknown. This study aimed to investigate whether N6022 mitigates cerebral ischemia/reperfusion (I/R) injury by reducing ferroptosis and to elucidate the underlying mechanisms. Accordingly, we established an oxygen-glucose deprivation/reperfusion (OGD/R) cell model and a middle cerebral artery occlusion/reperfusion (MCAO/R) mouse model to mimic cerebral I/R injury. Our data, both in vitro and in vivo, demonstrated that N6022 effectively protected against I/R-induced brain damage and neurological deficits in mice, as well as OGD/R-induced BV2 cell damage. Mechanistically, N6022 promoted Nrf2 nuclear translocation, enhancing intracellular antioxidant capacity of SLC7A11-GPX4 system. Furthermore, N6022 interfered with the interaction of GSNOR with GSTP1, thereby boosting the antioxidant capacity of GSTP1 and attenuating ferroptosis. These findings provide novel insights, showing that N6022 attenuates microglial ferroptosis induced by cerebral I/R injury through the promotion of Nrf2 nuclear translocation and inhibition of the GSNOR/GSTP1 axis.

100 Deals associated with N-6022

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12206

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain Cancer	Preclinical	United States	Texas Tech University Health Sciences Center	01 Jul 2017
Cystic Fibrosis	Preclinical	United States	Nivalis Therapeutics, Inc.	01 Feb 2014
Asthma	Preclinical	United States	Nivalis Therapeutics, Inc.	01 Mar 2011
Inflammatory Bowel Diseases	Preclinical	United States	Nivalis Therapeutics, Inc.	-
Pulmonary Disease, Chronic Obstructive	Preclinical	United States	Nivalis Therapeutics, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01746784 (SNO-1, CTgov)	Phase 1	Cystic Fibrosis	66	normal saline	nuclkewufh(srajsrtsdz) = wvaynxvwus fkchmxvwej (qhudstcupj, vdglbioqld - difeaktkqd) View more	-	24 Nov 2014
NCT01316315 (CTgov)	Phase 1/2	Asthma	14	Placebo (Placebo)	bskahwvhvh(esehfjruwc) = dyuhzmbvxu xiboarqjqk (jlrqsxgfjf, rsouhmzdtm - blwtydexsx) View more	-	11 Mar 2014
NCT01316315 (CTgov)	Phase 1/2	Asthma	14	Active (Active)	irlrdpbfgl(emyeidodrv) = qjablmmuwa ibmayhllav (ebbksveora, wgscwhznqj - jcyiefdyto) View more	-	11 Mar 2014
NCT01147406 (CTgov)	Phase 1	-	41	Placebo	ovcfwvgpjx(wyhuhbvuuo) = yisdjwoqtz kwmlcejgbd (lwitfdlrft, njuugsjlmr - jgndtpqngr) View more	-	07 Mar 2014